|
Gene: HUS1 |
Gene summary for HUS1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HUS1 | Gene ID | 3364 |
Gene name | HUS1 checkpoint clamp component | |
Gene Alias | hHUS1 | |
Cytomap | 7p12.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A4D2F2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3364 | HUS1 | HCC1_Meng | Human | Liver | HCC | 7.03e-34 | 4.99e-02 | 0.0246 |
3364 | HUS1 | HCC2_Meng | Human | Liver | HCC | 1.52e-03 | 3.07e-02 | 0.0107 |
3364 | HUS1 | HCC2 | Human | Liver | HCC | 9.66e-08 | 3.39e+00 | 0.5341 |
3364 | HUS1 | S014 | Human | Liver | HCC | 5.79e-12 | 4.05e-01 | 0.2254 |
3364 | HUS1 | S015 | Human | Liver | HCC | 7.53e-07 | 4.40e-01 | 0.2375 |
3364 | HUS1 | S016 | Human | Liver | HCC | 6.61e-09 | 3.55e-01 | 0.2243 |
3364 | HUS1 | S027 | Human | Liver | HCC | 6.28e-08 | 6.32e-01 | 0.2446 |
3364 | HUS1 | S028 | Human | Liver | HCC | 3.15e-21 | 7.65e-01 | 0.2503 |
3364 | HUS1 | S029 | Human | Liver | HCC | 3.93e-16 | 6.99e-01 | 0.2581 |
3364 | HUS1 | C04 | Human | Oral cavity | OSCC | 2.06e-15 | 6.95e-01 | 0.2633 |
3364 | HUS1 | C21 | Human | Oral cavity | OSCC | 1.10e-38 | 1.11e+00 | 0.2678 |
3364 | HUS1 | C30 | Human | Oral cavity | OSCC | 1.10e-28 | 1.27e+00 | 0.3055 |
3364 | HUS1 | C43 | Human | Oral cavity | OSCC | 3.25e-18 | 4.17e-01 | 0.1704 |
3364 | HUS1 | C46 | Human | Oral cavity | OSCC | 5.36e-03 | 1.17e-01 | 0.1673 |
3364 | HUS1 | C51 | Human | Oral cavity | OSCC | 3.76e-10 | 4.74e-01 | 0.2674 |
3364 | HUS1 | C57 | Human | Oral cavity | OSCC | 7.31e-10 | 3.40e-01 | 0.1679 |
3364 | HUS1 | C06 | Human | Oral cavity | OSCC | 4.82e-04 | 6.54e-01 | 0.2699 |
3364 | HUS1 | C08 | Human | Oral cavity | OSCC | 4.29e-27 | 4.94e-01 | 0.1919 |
3364 | HUS1 | C09 | Human | Oral cavity | OSCC | 1.37e-04 | 1.83e-01 | 0.1431 |
3364 | HUS1 | LN46 | Human | Oral cavity | OSCC | 1.39e-02 | 1.86e-01 | 0.1666 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
GO:0071479110 | Esophagus | ESCC | cellular response to ionizing radiation | 54/8552 | 72/18723 | 3.85e-07 | 5.32e-06 | 54 |
GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa0421822 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HUS1 | SNV | Missense_Mutation | c.232G>A | p.Glu78Lys | p.E78K | O60921 | protein_coding | deleterious(0.01) | benign(0.395) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HUS1 | insertion | Frame_Shift_Ins | novel | c.688_689insAACAATTTCTCATTGATGTTGTGAAAATCGTCATGTATTTAGA | p.Val230GlufsTer20 | p.V230Efs*20 | O60921 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
HUS1 | SNV | Missense_Mutation | c.183N>T | p.Glu61Asp | p.E61D | O60921 | protein_coding | tolerated(0.51) | benign(0.068) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HUS1 | SNV | Missense_Mutation | c.501G>T | p.Lys167Asn | p.K167N | O60921 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
HUS1 | SNV | Missense_Mutation | c.667N>C | p.Asn223His | p.N223H | O60921 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
HUS1 | SNV | Missense_Mutation | rs779721301 | c.341C>T | p.Thr114Met | p.T114M | O60921 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HUS1 | SNV | Missense_Mutation | c.416N>A | p.Pro139His | p.P139H | O60921 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HUS1 | SNV | Missense_Mutation | rs779721301 | c.341N>T | p.Thr114Met | p.T114M | O60921 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HUS1 | SNV | Missense_Mutation | novel | c.265N>C | p.Ser89Pro | p.S89P | O60921 | protein_coding | tolerated(0.19) | possibly_damaging(0.747) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HUS1 | SNV | Missense_Mutation | c.192N>A | p.Phe64Leu | p.F64L | O60921 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3364 | HUS1 | DNA REPAIR, KINASE | CAMPTOTHECIN | CAMPTOTHECIN | 14762204 |
Page: 1 |